RU2004126861A - Производные пиридинамидов в качестве ингибиторов моноаминоксидазы (мао-в) - Google Patents
Производные пиридинамидов в качестве ингибиторов моноаминоксидазы (мао-в) Download PDFInfo
- Publication number
- RU2004126861A RU2004126861A RU2004126861/04A RU2004126861A RU2004126861A RU 2004126861 A RU2004126861 A RU 2004126861A RU 2004126861/04 A RU2004126861/04 A RU 2004126861/04A RU 2004126861 A RU2004126861 A RU 2004126861A RU 2004126861 A RU2004126861 A RU 2004126861A
- Authority
- RU
- Russia
- Prior art keywords
- formula
- alkyl
- compounds
- halogen
- fluorobenzyloxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (18)
1. Соединения общей формулы
где один из Х или Уозначает -N=, а другой означает -CR7=;
R1 означает водород или (С1-С6)алкил;
R2 означает водород или (С1-С6)алкил;
R3 означает водород или (С1-С6)алкил;
R4 означает галоген(С1-С6)алкил или незамещенный арил, или арил, замещенный одним или несколькими заместителями, выбранными из группы, состоящей из (С1-С6)алкила, галогена, галоген(С1-С6)-алкила, (С1-С6)алкоксигруппы и циангруппы;
R5 означает водород или (С1-С6)алкил;
R6 означает водород или (С1-С6)алкил;
R7 означает водород или (С1-С6)алкил;
а также их фармацевтически приемлемые соли.
2. Соединения формулы I по п.1, где Х означает -N=.
3. Соединения формулы I по п.2, где R4 означает незамещенный арил или арил, замещенный одним или несколькими заместителями, выбранными из группы, состоящей из (С1-С6)алкила, галогена, галоген(С1-С6)алкила, (С1-С6)алкоксигруппы и циангруппы.
4. Соединения формулы I по п.3, где R4 означает фенил или фенил, замещенный одним или несколькими заместителями, выбранными из группы, состоящей из (С1-С6)-алкила, галогена, галоген(С1-С6)алкила, (С1-С6)алкоксигруппы и циангруппы.
5. Соединения формулы I по п.4, где R4 означает фенил, замещенный одним или несколькими атомами галогена.
6. Соединения формулы I по п.5, которые выбираются из группы, включающей
карбамоилметиламид 5-(3-фторбензилокси)пиридин-2-карбоновой кислоты,
карбамоилметиламид 5-(4-фторбензилокси)пиридин-2-карбоновой кислоты,
карбамоилметиламид 5-(3,4-дифторбензилокси)пиридин-2-карбоновой кислоты,
(1-карбамоилэтил)амид(S)-5-(3-фторбензилокси)пиридин-2-карбоновой кислоты,
(1-карбамоилэтил)амид(S)-5-(4-фторбензилокси)пиридин-2-карбоновой кислоты и
(1-карбамоилэтил)амид(S)-5-(3,4-дифторбензилокси)пиридин-2-карбоновой кислоты.
7. Соединения формулы I по п.1, где Y означает -N=.
8. Соединения формулы I по п.7, где R4 означает незамещенный арил или арил, замещенный одним или несколькими заместителями, выбранными из группы, состоящей из (С1-С6)алкила, галогена, галоген(С1-С6)алкила, (C1-С6)алкоксигруппы и циангруппы.
9. Соединения формулы I по п.8, где R4 означает фенил или фенил, замещенный одним или несколькими заместителями, выбранными из группы, состоящей из (С1-С6)-алкила, галогена, галоген(С1-С6)алкила, (С1-С6)алкоксигруппы и циангруппы.
10. Соединения формулы I по п.9, где R4 означает фенил или фенил, замещенный одним или несколькими атомами галогена.
11. Соединения формулы I по п.10, которые выбираются из группы, включающей:
6-бензилокси-N-карбамоилметилникотинамид,
N-карбамоилметил-6-(3-фторбензилокси)никотинамид,
N-карбамоилметил-6-(4-фторбензилокси)никотинамид,
(S)-6-бензилокси-N-(1-карбамоилэтил)никотинамид,
(S)-N-(1-карбамоилэтил)-6-(3-фторбензилокси)никотинамид и
(S)-N-(1-карбамоилэтил)-6-(4-фторбензилокси)никотинамид.
12. Способ получения соединения формулы I по п.1, а также его фармацевтически приемлемой соли, который включает взаимодействие соединения формулы
где X, Y, R4, R5 и R6 являются такими, как указано в п.1,
с соединением формулы
где R1, R2 и R3 являются такими, как указано в п.1,
для получения соединения формулы
и, если желательно, превращение соединения формулы I в фармацевтически приемлемую соль.
13. Соединение формулы I по любому из пп.1-11, полученное способом по п.12.
14. Лекарственное средство, содержащее одно или несколько соединений по любому из пп.1-11 и фармацевтически приемлемые наполнители, предназначенное для лечения и предупреждения заболеваний, опосредованных ингибиторами моноаминоксидазы В.
15. Лекарственное средство, содержащее одно или несколько соединений по любому из пп.1-11 и фармацевтически приемлемые наполнители, предназначенное для лечения и предупреждения болезни Альцгеймера и старческого слабоумия.
16. Соединение формулы I по любому из пп.1-11, а также его фармацевтически приемлемые соли для лечения или предупреждения заболеваний.
17. Применение соединения формулы I по любому из пп.1-11, а также его фармацевтически приемлемых солей для производства лекарственных средств, предназначенных для лечения и предупреждения заболеваний, опосредованных ингибиторами моноаминоксидазы В.
18. Применение по п.17, когда заболеванием является болезнь Альцгеймера или старческое слабоумие.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02001969.1 | 2002-02-04 | ||
EP02001969 | 2002-02-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2004126861A true RU2004126861A (ru) | 2005-05-27 |
RU2309950C2 RU2309950C2 (ru) | 2007-11-10 |
Family
ID=27675593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2004126861/04A RU2309950C2 (ru) | 2002-02-04 | 2003-01-27 | Производные пиридинамидов и лекарственное средство на их основе |
Country Status (13)
Country | Link |
---|---|
US (1) | US6667327B2 (ru) |
EP (1) | EP1474394A1 (ru) |
JP (1) | JP4217159B2 (ru) |
KR (1) | KR100621297B1 (ru) |
CN (1) | CN1261414C (ru) |
AR (1) | AR038342A1 (ru) |
AU (1) | AU2003205677B2 (ru) |
BR (1) | BR0307444A (ru) |
CA (1) | CA2473459A1 (ru) |
MX (1) | MXPA04007501A (ru) |
PL (1) | PL372226A1 (ru) |
RU (1) | RU2309950C2 (ru) |
WO (1) | WO2003066596A1 (ru) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2543287A1 (en) * | 2003-10-23 | 2005-05-06 | F.Hoffmann-La Roche Ag | Benzazepine derivatives as mao-b inhibitors |
UA90708C2 (ru) | 2005-02-25 | 2010-05-25 | Ф. Хоффманн-Ля Рош Аг | Таблетки с улучшенной дисперсностью лекарственного вещества |
WO2006138475A2 (en) * | 2005-06-16 | 2006-12-28 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
WO2011035324A1 (en) * | 2009-09-21 | 2011-03-24 | Vanderbilt University | O-benzyl nicotinamide analogs as mglur5 positive allosteric modulators |
IT1404729B1 (it) * | 2011-01-27 | 2013-11-29 | Univ Pisa | Inibitori altamente selettivi dell'attivita' di adams |
KR101746060B1 (ko) | 2015-09-18 | 2017-06-12 | 한국과학기술연구원 | 항비만 치료용 가역적 마오비 저해제 |
CN105601563B (zh) * | 2015-12-17 | 2018-05-08 | 浙江工业大学 | 6-氯-n-(4-(6-氯烟酰胺)苄基)烟酰胺及其制备和应用 |
CN108912029B (zh) * | 2017-08-25 | 2021-10-01 | 广东东阳光药业有限公司 | 含氮杂环酰胺衍生物及其用途 |
CN107903289B (zh) * | 2017-11-08 | 2020-07-31 | 中国科学院烟台海岸带研究所 | 一种基于花菁的有机化合物及其应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1261335A (en) | 1984-08-29 | 1989-09-26 | Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee | Ethylenediamine monoamide derivatives |
CN86106435A (zh) * | 1985-09-24 | 1987-05-27 | 舍林股份公司 | 咪唑啉基衍生物,其制备方法和含有这类化合物的具有除草作用的制剂 |
JPH02142774A (ja) | 1988-11-25 | 1990-05-31 | Mitsui Toatsu Chem Inc | 2−(4−置換フェニル)イミダゾリノン類、その製造法、およびそれらを有効成分として含有する除草剤 |
IL94466A (en) | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
CA2090857A1 (en) | 1990-09-17 | 1992-03-18 | David A. Clark | 5-trifluoroacylamino-2-aryloxazoles 2-aryl-5-trifluoroacylaminooxazoles |
GB9306886D0 (en) | 1993-04-01 | 1993-05-26 | Erba Carlo Spa | Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation |
GB9515412D0 (en) | 1995-07-27 | 1995-09-27 | Pharmacia Spa | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives |
AU751022B2 (en) | 1997-09-19 | 2002-08-08 | Wyeth Holdings Corporation | Peptides derived from the attachment (G) protein of respiratory syncytial virus |
EP2201944B1 (en) | 1997-11-21 | 2012-05-23 | Purdue Neuroscience Company | Use of substituted 2-aminoacetamides for treating, preventing or ameliorating manic depression |
GB9727521D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Substituted 2-benzylamino-2-phenyl-acetamide compounds |
AU3654099A (en) | 1998-04-20 | 1999-11-08 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted amino acids as erythropoietin mimetics |
US6294694B1 (en) | 1999-06-04 | 2001-09-25 | Wisconsin Alumni Research Foundation | Matrix metalloproteinase inhibitors and method of using same |
DE19952146A1 (de) | 1999-10-29 | 2001-06-07 | Boehringer Ingelheim Pharma | Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US6306911B1 (en) | 2000-02-07 | 2001-10-23 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted amino acids as neutral sphingomyelinase inhibitors |
-
2003
- 2003-01-14 US US10/341,672 patent/US6667327B2/en not_active Expired - Fee Related
- 2003-01-27 AU AU2003205677A patent/AU2003205677B2/en not_active Ceased
- 2003-01-27 EP EP03702531A patent/EP1474394A1/en not_active Withdrawn
- 2003-01-27 CN CNB038032651A patent/CN1261414C/zh not_active Expired - Fee Related
- 2003-01-27 WO PCT/EP2003/000769 patent/WO2003066596A1/en active Application Filing
- 2003-01-27 MX MXPA04007501A patent/MXPA04007501A/es active IP Right Grant
- 2003-01-27 CA CA002473459A patent/CA2473459A1/en not_active Abandoned
- 2003-01-27 JP JP2003565970A patent/JP4217159B2/ja not_active Expired - Fee Related
- 2003-01-27 RU RU2004126861/04A patent/RU2309950C2/ru not_active IP Right Cessation
- 2003-01-27 KR KR1020047011975A patent/KR100621297B1/ko not_active IP Right Cessation
- 2003-01-27 BR BR0307444-7A patent/BR0307444A/pt not_active IP Right Cessation
- 2003-01-27 PL PL03372226A patent/PL372226A1/xx not_active Application Discontinuation
- 2003-02-03 AR ARP030100319A patent/AR038342A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR0307444A (pt) | 2004-12-28 |
AR038342A1 (es) | 2005-01-12 |
CN1261414C (zh) | 2006-06-28 |
JP4217159B2 (ja) | 2009-01-28 |
KR20040082407A (ko) | 2004-09-24 |
US6667327B2 (en) | 2003-12-23 |
AU2003205677B2 (en) | 2008-04-24 |
AU2003205677A1 (en) | 2003-09-02 |
CN1628102A (zh) | 2005-06-15 |
EP1474394A1 (en) | 2004-11-10 |
JP2005528339A (ja) | 2005-09-22 |
KR100621297B1 (ko) | 2006-09-13 |
CA2473459A1 (en) | 2003-08-14 |
PL372226A1 (en) | 2005-07-11 |
WO2003066596A1 (en) | 2003-08-14 |
MXPA04007501A (es) | 2004-11-10 |
RU2309950C2 (ru) | 2007-11-10 |
US20030158235A1 (en) | 2003-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2403251C2 (ru) | Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 | |
RU2397168C2 (ru) | Производные тиофена в качестве ингибиторов снк 1 | |
RU2005111968A (ru) | Производные 4-пирролидинофенилбензилового эфира | |
RU2003117719A (ru) | Профилактические или лечебные лекарственные средства от диабета, содержащие конденсированные гетероциклические соединения или их соли | |
RU2007139453A (ru) | Гетеробициклические ингибиторы вируса гепатита с (hcv) | |
RU2005121908A (ru) | Производные зн-хиназолин-4-она | |
HUP0402310A2 (hu) | 1,6-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények | |
JP2004518723A5 (ru) | ||
RU2005104104A (ru) | Производные амида коричной кислоты | |
MA28097A1 (fr) | Derives de n-[heteroaryl(piperidin-2-yl)methyl] benzamide, leur preparation et leur application en therapeutique | |
JP2005522480A5 (ru) | ||
JP2013509392A5 (ru) | ||
RU2012112050A (ru) | Производные дигидроптеридинона, способ их получения и фармацевтическое применение | |
JP2006502119A5 (ru) | ||
JP2005530811A5 (ru) | ||
NO20045497L (no) | Fremgangsmate for fremstilling av 5-(1,3-oksazol-2-yl)benzosyrederivater | |
RU2005100755A (ru) | Фторбензамиды | |
CA2533763A1 (en) | Cyanoamide compounds useful as malonyl-coa decarboxylase inhibitors | |
RU2004126861A (ru) | Производные пиридинамидов в качестве ингибиторов моноаминоксидазы (мао-в) | |
ATE450496T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
CA2526991A1 (en) | Piperidinium and pyrrolidinium derivatives as ligands for the muscarinic m3 receptor | |
CA2575512A1 (en) | Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors | |
RU2004131651A (ru) | Фталимидопроизводные в качестве ингибиторов моноаминооксидазы в | |
JP2006523626A5 (ru) | ||
JP2005529869A5 (ru) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20110128 |